Follow @dorgang

Follow @snbchf

Home › 3) Swiss Markets and News › 3.) Swissinfo Business and Economy › Swiss pharma giant Novartis to close biotech firm Morphosys

Previous post Next post

Swiss pharma giant Novartis to close biotech firm Morphosys

Published on December 19, 2024

See on Internet Archive

by
Swissinfo
My articles My site About me My videos My books
Follow on:Twitter Facebook Google +

Swiss pharma giant Novartis to close biotech firm Morphosys — Novartis acquired Morphosys earlier this year for a total of €2.7 billion (CHF2.5 billion). Keystone-SDA

Generated with artificial intelligence.

Novartis is closing the German biotech company Morphosys, acquired earlier this year, according to German press reports confirmed by the Basel-based pharmaceutical giant. Hundreds of jobs are affected.

This content was published on December 19, 2024 - 14:40

Novartis decided in November 2024 to close the Morphosys sites in Germany and the United States by the end of 2025 and integrate all portfolio activities into the company, according to an article in the German magazine WirtschaftsWoche on Thursday. Around 330 jobs could be lost. Contacted by the AWP news agency, the Basel-based pharmaceutical giant confirmed this information.

+Get the most important news from Switzerland in your inbox

Novartis acquired Morphosys earlier this year for a total of €2.7 billion (CHF2.5 billion). With this acquisition, the Basel-based company was hoping to gain access to Pelabresib, a treatment in development for myelofibrosis, a potentially fatal chronic bone marrow disease.

But concerns have recently arisen about the efficacy and safety of this promising drug, according to the German magazine. A few weeks ago, Novartis re-assessed Morphosys and corrected its value by $800 million.

+ Novartis CEO: ‘Our strategy is bearing fruit’

“All merger-and-acquisition activities in research and development involve a certain degree of risk and depend on circumstances. Novartis regularly reviews its portfolio and organizational structure in order to be better positioned for the future and to meet patients’ needs,” the Basel-based pharmaceutical giant explained to WirtschaftsWoche.

Morphosys was founded in 1992 and is one of Germany’s oldest biotech companies. Until recently, the company’s shares were listed in Frankfurt and New York.

Translated from French with DeepL/gw

This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles.

If you want to know more about how we work, have a look here, if you want to learn more about how we use technology, click here, and if you have feedback on this news story please write to [email protected].

Swisscom receives greenlight for acquisition of Vodafone Italia

This content was published on Dec 21, 2024 The takeover of Vodafone Italia by Swisscom is nearing completion. All relevant authorities have now approved the €8 billion (CHF7.45 billion) deal.

Novo Nordisk stock market plunge drags down Swiss device maker Ypsomed

This content was published on Dec 21, 2024 The Danish pharmaceutical giant, Novo Nordisk, faced setbacks on Friday that weighed on the share price of Swiss injection device manufacturer Ypsomed.

Swiss press react to EU deal with mix of euphoria and scepticism

This content was published on Dec 21, 2024 Swiss media reaction to the agreement between Switzerland and the EU varies widely. Some are celebrating, while others worry about what is to come.

Swiss Solidarity donations to tackle child abuse top CHF4 million

This content was published on Dec 21, 2024 Swiss Solidarity, the humanitarian arm of the Swiss Broadcasting Corporation (SBC), has raised over CHF4 million ($4.3 million) to tackle child abuse.

Most Swiss companies consider sustainability in supplier selection

This content was published on Dec 21, 2024 The majority of large listed Swiss companies pay attention to sustainability when choosing their suppliers.

Swiss president is ‘shocked’ by attack on German Christmas market

This content was published on Dec 21, 2024 Swiss President Viola Amherd has expressed her shock at the attack in Magdeburg.

Swiss security strategy will prioritise cyberdefence and NATO cooperation

This content was published on Dec 20, 2024 The aim is to reduce vulnerabilities and increase Switzerland's defensive capabilities.

EU Commission president says Swiss-EU deal is ‘historic’ agreement

This content was published on Dec 20, 2024 At a joint media conference with Swiss President Viola Amherd in Bern, European Commission President Ursula von der Leyen spoke of a "day of joy".

Switzerland and EU reach deal on future bilateral relations

This content was published on Dec 20, 2024 Switzerland and the European Union have announced a political agreement to update their trading relationship after almost a decade of difficult talks.

Switzerland could build new nuclear power plants

This content was published on Dec 20, 2024 The Swiss government has opened up the possibility of new nuclear power plants in response to a people's initiative.

Full story here Are you the author?

About Swissinfo

SWI swissinfo.ch – the international service of the Swiss Broadcasting Corporation (SBC). Since 1999, swissinfo.ch has fulfilled the federal government’s mandate to distribute information about Switzerland internationally, supplementing the online offerings of the radio and television stations of the SBC. Today, the international service is directed above all at an international audience interested in Switzerland, as well as at Swiss citizens living abroad.

My articles My site About me My books
Follow on:Twitter Facebook Google +